Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease

详细信息    查看全文

• 作者：Holger Budde ; Marie-Sophie Sorns ; Pia Welker ; Kai Licha…
• 关键词：Dendritic polyglycerol sulfate ; Heparin derivatives ; GvHD ; Inflammation
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：95
• 期：3
• 页码：465-472
• 全文大小：541 KB
• 参考文献：1.Wood RM, Bick MW (1959) A comparison of the influence of parenteral trypsin, cortisone, and heparin on acute inflammation. AMA Arch Ophthalmol 62:112–116CrossRef PubMed
  2.Dolowitz DA, Dougherty TF (1960) The use of heparin as an anti-inflammatory agent. Laryngoscope 70:873–884PubMed
  3.Grant L, Palmer P, Sanders AG (1962) The effect of heparin on the sticking of white cells to endothelium in inflammation. J Pathol Bacteriol 83:127–133CrossRef PubMed
  4.Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253–3258PubMed
  5.Wang H, Asavaroengchai W, Yeap BY, Wang MG, Wang S, Sykes M, Yang YG (2009) Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 110:127–136CrossRef
  6.Hochart H, Jenkins PV, Smith OP, White B (2006) Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 133:62–67CrossRef PubMed
  7.Türk H, Haag R, Alban S (2002) Dendritic polyglycerol sulfates as new heparin analogues and potent inhibitors of the complement system. Bioconjug Chem 15:162–167CrossRef
  8.Frey H, Haag R (2002) Dendritic polyglycerol: a new versatile biocompatible-material. J Biotechnol 90:257–267PubMed
  9.Weinhart M, Gröger D, Enders S, Dernedde J, Haag R (2011) Synthesis of dendritic polyglycerol anions and their efficiency toward L-selectin inhibition. Biomacromolecules 12:2502–2511CrossRef PubMed
  10.Khandare J, Mohr A, Calderón M, Welker P, Licha K, Haag R (2010) Structure-biocompatibility relationship of dendritic polyglycerol derivatives. Biomaterials 31:4268–4277CrossRef PubMed
  11.Dernedde J, Rausch A, Weinhart M, Enders S, Tauber R, Licha K, Schirner M, Zügel U, von Bonin A, Haag R (2010) Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proc Natl Acad Sci USA 107:19679–19684PubMedCentral CrossRef PubMed
  12.Shlomchik WD (2007) Graft-versus-host disease. Nat Rev Immunol 7:340–352CrossRef PubMed
  13.Ball LM, Egeler RM (2008) EBMT Paediatric Working Party. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 41:58–64CrossRef
  14.Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12:443–458PubMedCentral CrossRef PubMed
  15.Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550–1561PubMedCentral CrossRef PubMed
  16.Dhir S, Slatter M, Skinner R (2014) Recent advances in the management of graft-versus-host disease. Arch Dis Child 99:1150–1157CrossRef PubMed
  17.Tischner D, Theiss J, Karabinskaya A, van den Brandt J, Reichardt SD, Karow U, Herold MJ, Lühder F, Utermöhlen O, Reichardt HM (2011) Acid sphingomyelinase is required for protection of effector memory T cells against glucocorticoid-induced cell death. J Immunol 187:4509–4516CrossRef PubMed
  18.Budde H, Kolb S, Salinas Tejedor L, Wulf G, Reichardt HM, Riggert J, Legler TJ (2014) Modified extracorporeal photopheresis with cells from a healthy donor for acute graft-versus-host disease in a mouse model. PLoS One 9:e105896PubMedCentral CrossRef PubMed
  19.Korngold R (1992) Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant 9:355–364PubMed
  20.Naparstek E, Slavin S, Weiss L, Sidi H, Ohana M, Reich S et al (1993) Low-dose heparin inhibits acute graft versus host disease in mice. Bone Marrow Transplant 12:185–189PubMed
  21.Paulus F, Schulze R, Steinhilber D, Zieringer M, Steinke I, Welker P, Licha K, Wedepohl S, Dernedde J, Haag R (2014) The effect of polyglycerol sulfate branching on inflammatory processes. Macromol Biosci 14:643–654CrossRef PubMed
  22.Pant K, Gröger D, Bergmann R, Pietzsch J, Steinbach J, Graham B et al (2015) Synthesis and biodistribution studies of (3)h- and (64)cu-labeled dendritic polyglycerol and dendritic polyglycerol sulfate. Bioconjug 26:906–918CrossRef
  23.Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S (2013) Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer 4:25–35PubMedCentral CrossRef PubMed
  24.Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS (2010) NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115:4293–4301PubMedCentral CrossRef PubMed
  25.Levine JE (2011) Implications of TNF-α in the pathogenesis and management of GVHD. Int J Hematol 93:571–577PubMedCentral CrossRef PubMed
  26.Maysinger D, Gröger D, Lake A, Licha K, Weinhart M, Chang PK et al (2015) Dendritic polyglycerol sulfate inhibits microglial activation and reduces hippocampal CA1 dendritic spine morphology deficits. Biomacromolecules 16:3073–3082CrossRef PubMed
  27.Ellison CA, Natuik SA, McIntosh AR, Scully SA, Danilenko DM, Gartner JG (2003) The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice. Immunology 109:440–449PubMedCentral CrossRef PubMed
  28.Wang H, Asavaroengchai W, Yeap BY, Wang MG, Wang S, Sykes M, Yang YG (2009) Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood 113:3612–3619PubMedCentral CrossRef PubMed
  29.Asavaroengchai W, Wang H, Wang S, Wang L, Bronson R, Sykes M et al (2007) An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 13:46–55PubMedCentral CrossRef PubMed
  30.Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y et al (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5:179ra43PubMedCentral CrossRef PubMed
  31.Kennedy-Nasser AA, Ku S, Castillo-Caro P, Wu MF, Liu H, Melenhorst J et al (2014) Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 20:2215–2225PubMedCentral CrossRef PubMed
  32.Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP et al (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055–2066PubMedCentral CrossRef PubMed
  33.Bethge WA, Kerbauy FR, Santos EB (2014) Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD. Bone Marrow Transplant 49:1198–1204PubMedCentral CrossRef PubMed
  
• 作者单位：Holger Budde (1)
  Marie-Sophie Sorns (1)
  Pia Welker (2)
  Kai Licha (2)
  Hendrik Wolff (3)
  Joachim Riggert (1)
  Gerald Wulf (4)
  Tobias J. Legler (1)
  
  1. Department of Transfusion Medicine, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany
  2. mivenion GmbH, Robert-Koch-Platz 4, 10115, Berlin, Germany
  3. Department of Radiotherapy and Radiooncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany
  4. Department of Hematology and Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Graft-versus-host disease (GvHD) is a severe immune reaction commonly occurring after hematopoietic stem cell transplantation. The outcome of patients who do not respond to the currently used immunosuppressive drugs is poor, thus there is an urgent need for the evaluation of new therapies. Heparin has a well-known anti-inflammatory effect and heparin analogues with a low anticoagulant effect are interesting candidates as new anti-inflammatory drugs. We explored the therapeutic potential of dendritic polyglycerol sulfates (dPGS), a novel class of heparin derivatives, on murine acute GvHD in vivo. The therapeutic effect of dPGS on murine GvHD was more intense after intravenous application compared to subcutaneous injection. An increased survival rate and improved clinical scores were observed in mice treated with 5 mg/kg once a week. In these animals, there was a reduction in the percentage of CD4+ and CD8+ T cells, which are the main effectors of GvHD. In addition, dPGS treatment decreased the number of tumor necrosis factor alpha (TNFα)-producing T cells. Increasing the dose of dPGS reversed the positive effect on survival as well as the clinical score, which indicates a small therapeutic range. Here, we report for the first time that dPGS have a significant immunosuppressive in vivo effect in a mouse model of severe acute GvHD. Therefore, we propose to study dPGS as promising candidates for the development of potential new drugs in the treatment of steroid-refractory GvHD patients first in larger animals and later in humans. Keywords Dendritic polyglycerol sulfate Heparin derivatives GvHD Inflammation